- Program Overview
• Start Date: August 16, 2026.
• Duration: Supported for up to two years.
• Mission: To prepare the next generation of scientists for leadership roles in academia, the
pharmaceutical industry, and regulatory agencies.
• Research Focus: Pharmacognosy and bioactive natural products research in complementary and
integrated health.
Exceptional Training Opportunities
Trainees benefit from trans-disciplinary approach coordinated in the Department of Pharmaceutical Sciences (PSCI). Key components include:
• Professional Development: Creation of an Individual Development Plan (IDP) and participation in
"Grant Writing for New Investigators".
• Scientific Rigor: Mandatory training in the Responsible Conduct of Research (RCR) and Natural
Products Integrity.
• Networking & Outreach: Opportunities for national conference presentations and public
outreach via the Atkins Garden Walk.
- Citizenship: Must be a U.S. citizen or Legal Permanent Resident (LPR).
- Education: Must have completed all Ph.D. requirements (preferably in pharmacognosy, medicinal chemistry, or a related field).
- Commitment: Trainees must dedicate their activities fully to the T32 program.
1. Curriculum Vitae (CV).
2. Research & Training Summary (1-2 pages): Outline the project and its relevance to
pharmacognosy and bioactive natural products research and identify a UIC T32 mentor.
3. Project Milestones & Funding Plan: Outline completion dates and describe plans for individual funding eBorts (e.g., F32) in coordination with the identified UIC T32 mentor.
4. Three Letters of Recommendation: one must be from the Ph.D. advisor; all must be sent directly to the program.
5. By mentor One-page nomination including: current funding that can support instrumentation and laboratory supplies for the candidate’s project; plan on how the mentor will contribute to the T32 training program.
Application Deadline & Questions: for questions and to submit nomination packages, please contact T32 Program Coordinator, Elizabeth Ryan (ryan@uic.edu)
Program Directors: Drs. Guido Pauli and Jimmy Orjala